Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes
Year: 2015
Type: article
Abstract: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a newly approved class of glucose-lowering medications with a novel mechanism of action. These agents increase glycosuria, which leads to improved glucose control. They also produce an osmotic diuresis that, in part, contributes to blood pressure reduction and calorie loss secondary to glycosuria leading to weight loss (1,2).
A recent review of SGLT2 inhibitors focuses on the blood pressure–lowering effects of the two approved glucose-lowering agents, dapagliflozin and canagliflozin (3). While not approved as antihypertensive agents, they may potentially aid in lowering blood pressure in patients with diabetes. A review of studies in both hypertensive and normotensive patients with type 2 diabetes demonstrates a 4–10 mmHg reduction of systolic blood pressure (3).
In this issue of Diabetes Care , Tikkanen et al. (4) investigate the effectiveness and safety of the newest agent in this class, empagliflozin, on blood pressure using 24-h ambulatory blood pressure monitoring. This study randomized over 800 subjects with type 2 diabetes, mean age of 60 years, and good kidney function (i.e., a mean estimated glomerular filtration rate [eGFR] of 84 mL/min/1.73 m2). These subjects either were normotensive (<140/90 mmHg) or had stage 1 hypertension (≥140/90 < 160/99 mmHg). They were randomized to either empagliflozin 10 mg daily, empagliflozin 25 mg …
Source: Diabetes Care
DOI: 10.2337/dc14-1596
Authors: Colleen Majewski, George L. Bakris
Institutions: University of Chicago, University of Chicago Medical Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2127413863
